Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome.

Peterson PK, Shepard J, Macres M, Schenck C, Crosson J, Rechtman D, Lurie N.

Am J Med. 1990 Nov;89(5):554-60.

PMID:
2239975
2.

A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome.

Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J.

Am J Med. 1990 Nov;89(5):561-8.

PMID:
2146875
3.

Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome.

Steinberg P, McNutt BE, Marshall P, Schenck C, Lurie N, Pheley A, Peterson PK.

J Allergy Clin Immunol. 1996 Jan;97(1 Pt 1):119-26.

PMID:
8568124
4.

Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome.

Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D, Tymms K, Wakefield D, Dwyer J, Lloyd A.

Am J Med. 1997 Jul;103(1):38-43.

PMID:
9236484
5.

A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome.

Peterson PK, Pheley A, Schroeppel J, Schenck C, Marshall P, Kind A, Haugland JM, Lambrecht LJ, Swan S, Goldsmith S.

Arch Intern Med. 1998 Apr 27;158(8):908-14.

PMID:
9570178
6.

Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial.

Lloyd AR, Hickie I, Brockman A, Hickie C, Wilson A, Dwyer J, Wakefield D.

Am J Med. 1993 Feb;94(2):197-203.

PMID:
8430715
7.

Cognitive behavioural therapy in chronic fatigue syndrome: a randomised controlled trial of an outpatient group programme.

O'Dowd H, Gladwell P, Rogers CA, Hollinghurst S, Gregory A.

Health Technol Assess. 2006 Oct;10(37):iii-iv, ix-x, 1-121.

8.

Influenza vaccination: is it appropriate in chronic fatigue syndrome?

Sleigh KM, Marra FH, Stiver HG.

Am J Respir Med. 2002;1(1):3-9. Review.

PMID:
14720070
9.

Sick building syndrome (SBS) and exposure to water-damaged buildings: time series study, clinical trial and mechanisms.

Shoemaker RC, House DE.

Neurotoxicol Teratol. 2006 Sep-Oct;28(5):573-88. Epub 2006 Aug 7.

PMID:
17010568
10.

A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome.

McDermott C, Richards SC, Thomas PW, Montgomery J, Lewith G.

QJM. 2006 Jul;99(7):461-8. Epub 2006 Jun 29.

PMID:
16809351
11.

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC; REFLEX Trial Group.

Arthritis Rheum. 2006 Sep;54(9):2793-806.

12.

Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome.

Forsyth LM, Preuss HG, MacDowell AL, Chiazze L Jr, Birkmayer GD, Bellanti JA.

Ann Allergy Asthma Immunol. 1999 Feb;82(2):185-91.

PMID:
10071523
13.

Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.

Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, Hendricks R, Krüger B, Kuklinski B, Meister H, Otto HJ, Rink C, Rösch W, Stauch S.

Hepatology. 1997 Jun;25(6):1351-60.

PMID:
9185752
14.
15.

Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy individuals.

Buchwald D, Pearlman T, Umali J, Schmaling K, Katon W.

Am J Med. 1996 Oct;101(4):364-70.

PMID:
8873506
16.
18.

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2003 Jun;48(6):1667-75.

19.

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.

Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL.

Pediatrics. 2001 Sep;108(3):E48.

PMID:
11533366
20.

Supplemental Content

Support Center